GlassScriptPhysician profile
William Whitemore Robison
NPI 1467457325
$15,303.52
in general payments reported to CMS, 2019-2025
49 companies · $2,499 in 2025
The $2,499 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,190 · 2020: $2,021 · 2021: $1,764 · 2022: $1,782 · 2023: $2,432 · 2024: $2,615 · 2025: $2,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,471 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,471.11 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,133.34 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,006.46 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,645.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,062.63 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $984.71 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $963.89 | 2019-2025 | Jardiance |
| Amgen INC. | $891.13 | 2019-2025 | Repatha, Evenity, Repatha |
| Glaxosmithkline, LLC. | $862.20 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $466.21 | 2022-2024 | |
| Currax Pharmaceuticals LLC | $387.69 | 2020-2023 | Nexletol, Contrave, Nexlizet |
| Amarin Pharma, INC. | $384.37 | 2019-2021 | |
| Corcept Therapeutics | $379.28 | 2023-2025 | Korlym |
| Merck Sharp & Dohme LLC | $376.81 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Abbvie INC. | $248.53 | 2021-2025 | Ubrelvy |
| Novartis Pharmaceuticals Corporation | $210.93 | 2019-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Robison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.